Dear Editor, Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by the JC virus (JCV). [1] PML is caused by lytic infection of glial cells in severely immunosuppressed patients and is often fatal. [2] JCV infects most people in childhood and is usually asymptomatic. Afterwards, the virus persists in the body in a latent state, where viral protein expression cannot be detected and replication occurs only episodically and at the low levels. [3, 4] Blood samples taken from healthy individuals indicate that 50-90% of adults have been exposed to this virus, with 19-27% shed JC virus in their urine. [5, 6] The JC virus can be detected by PCR in the urine of a third of healthy individuals or immunosuppressed patients with or without PML. [5, 7, 8] However, the JC virus is not usually found in the blood of immunocompetent individuals. Detection of JCV in blood is correlated with immunosuppression and not with PML. [8] Currently, there is no blood biomarker of JCV activity that may be used to diagnose PML. [1] A failure to detect JCV DNA in the CSF sample does not rule out the possibility of having PML, particularly in the earlier stages of the disease. [1] However, a false positive JCV test happens in 1-4% of HIV positive people. [9, 10] Wollebo [11] also pointed out the presence of robust levels of TNF-α and TNFR1 in clinical samples of PML lesions from an HIV patient. Table 1 gives the comparison of various diagnostic methods which have been assessed and also shows that how and where a new biomarker can be placed if a special biomarker for JCV reactivation is detected. The author proposes a 
